nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2025, 02, v.44 141-144+150
“瘀毒”理论指导下从“肺热络瘀”论治特发性肺纤维化
基金项目(Foundation): 国家自然科学基金项目(编号:82004285);国家自然科学基金项目(编号:81874442); 泰山学者工程专项经费资助项目(编号:tsqn202306392)
邮箱(Email): huxizhijia@126.com;
DOI: 10.16295/j.cnki.0257-358x.2025.02.003
发布时间: 2025-02-05
出版时间: 2025-02-05
移动端阅读
摘要:

特发性肺纤维化属于中医学肺痿、肺痹范畴。从实邪致病角度出发,查阅古今文献,发现本病与瘀毒的累积关系密切,结合临床可从“肺热络瘀”角度出发阐释本病病机,“肺热络瘀”贯穿疾病始终。在中医“瘀毒”理论指导下,从中西医结合角度出发,以清热、解毒、通络为治疗的基本原则,并根据临床症状做出辨证论治,获效颇佳。

Abstract:

Idiopathic pulmonary fibrosis considered within the scope of lung atrophy and lung impediment in traditional Chinese medicine(TCM). From the perspective of excess evil causing diseases,a review of ancient and modern literature reveals that this disease is closely related to the accumulation of blood stasis and toxins. Based on clinical practice,the disease cause of this disease can be explained from the perspective of “lung heat and collateral stasis”,which runs through the entire course of the disease. Under the guidance of the theory of “stasis toxins” in TCM,this paper explores the disease from the perspective of integrating traditional Chinese and western medicine,taking clearing heat,detoxifying and unblocking collaterals as the primary principles of treatment,and making differential diagnosis and treatment based on clinical symptoms,achieving remarkable results.

参考文献

[1] RAGHU G,REMY-JARDIN M,RICHELDI L,et al. Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults:an official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med,2022,205(9):e18-e47.

[2]车丽,张伟.血瘀对肺间质纤维化的影响[J].吉林中医药,2014,34(2):111-113.

[3]朱玉龙. 120例特发性肺间质纤维化患者证型分布特点及其与血液流变学,凝血功能相关性研究[D].乌鲁木齐:新疆医科大学,2010.

[4]刘骅漫,贾新华,田丽,等.从“毒损肺络”理论探讨特发性肺纤维化肌成纤维细胞活化机制[J].中华中医药杂志,2022,37(2):646-649.

[5]郗瑞席,孟闫燕,杨巧宁,等.冠心病“瘀”、“毒”从化与综合防治[J].中西医结合心脑血管病杂志,2013,11(6):641-642.

[6]黄丽娜,张伟.从毒损肺络辨治肺间质纤维化[J].时珍国医国药,2018,29(5):1150-1151.

[7]吕晓东,庞立健,刘创.肺络结构和功能与特发性肺纤维化急性发作期“肺热络瘀”病机[J].世界科学技术-中医药现代化,2014,16(9):1980-1983.

[8]孙志宏.简明医彀[M].北京:人民卫生出版社,1984:84.

[9]任培中,高金柱,樊茂蓉,等.从虚喘论治特发性肺纤维化的思路与方法[J].中医杂志,2017,58(11):929-932.

[10]吴以岭.中医络病学说与三维立体网络系统[J].中医杂志,2003,44(6):407-409.

[11] FARKAS L,GAULDIE J,VOELKEL N F,et al. Pulmonary hypertension and idiopathic pulmonary fibrosis:a tale of angiogenesis,apoptosis,and growth factors[J].Am J Respir Cell Mol Biol,2011,45(1):1-15.

[12]赵勤萍.肺间质纤维化中医证治探讨[J].山西中医学院学报,2005,6(1):34-35.

[13]丁明桥,许朝霞,王鹏.肺间质纤维化的中医发病机制探讨[J].辽宁中医杂志,2009,36(8):1291-1292.

[14]柴立民,刘涓,王珍,等.从“肺络微型癥瘕”论治特发性肺纤维化[J].广西中医药,2012,35(2):44-45.

[15]范锐,张伟.从气虚痰阻探讨肺纤维化氧化应激机制[J].中医杂志,2019,60(24):2099-2102.

[16]吴以岭.络病病机特点与病机变化[J].疑难病杂志,2004,3(5):282-284.

[17]于睿智,庞立健,王天娇,等.从虚、毒、痰、瘀辨治特发性肺纤维化[J].中华中医药杂志,2022,37(10):5815-5818.

[18]李阳,吴志松,刘肇恒,等.铁死亡与特发性肺间质纤维化中医病机的相关性[J/OL].中医学报,1-9[2024-12-23].

[19]李晓明,李作盐,石坷,等.补阳还五汤抑制大鼠肺纤维化及对肺组织TGF-β/Smads信号通路的影响[J].山东医药,2021,61(5):36-39.

[20]宋思雨,丁露,赵美茹,等.特发性肺纤维化中医病机及防治策略的研究进展[J].中华中医药杂志,2024,39(11):6020-6025.

[21]于睿智,吕晓东,庞立健,等.刍议清络法论治特发性肺纤维化急性发作[J].世界科学技术-中医药现代化,2021,23(11):4305-4309.

[22]庞立健,吕晓东,袁佺,等.益气养阴活血通络法干预肺成纤维细胞TGF-β1/Smads信号传导通路的机制[J].中国实验方剂学杂志,2017,23(22):125-131.

[23]李辉,李国勤,刘俊玲,等.益气活血通络法对特发性肺纤维化患者生存质量的影响[J].北京中医药大学学报,2010,33(3):214-216.

[24]张艳霞,史利卿,杨效华,等.补气活血通络方干预肺纤维化大鼠PI3K/AKT信号通路研究[J].北京中医药大学学报,2018,41(11):905-909,917.

[25] QIAN W,CAI X,QIAN Q,et al. Angelica sinensispolysaccharide suppresses epithelial-mesenchymal transition and pulmonary fibrosis via a DANCR/AUF-1/FOXO3regulatory axis[J]. Aging Dis,2020,11(1):17-30.

[26] ZHANG Y,GU L,XIA Q,et al. Radix Astragali and Radix Angelicae Sinensis in the treatment of idiopathic pulmonary fibrosis:a systematic review and meta-analysis[J]. Front Pharmacol,2020,11:415.

[27] KING T E,BRADFORD W Z,CASTRO-BERNARDINI S,et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med,2014,370(22):2083-2092.

[28] RICHELDI L,DU BOIS R M,RAGHU G,et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med,2014,370(22):2071-2082.

[29]王菲,黄艳,刘鑫,等.肺纤康颗粒联合吡非尼酮治疗肺虚络瘀型特发性肺纤维化的临床研究[J].中国处方药,2024,22(10):1-6.

[30]王丽娜,罗竹,黄小朵,等.黄芪-丹参药对对特发性肺纤维化小鼠肺泡炎症及纤维化的影响[J].中成药,2020,42(6):1600-1604.

[31]张小强.益宗通络方治疗特发性肺纤维化气虚血瘀证的临床疗效观察[D].乌鲁木齐:新疆医科大学,2024.

基本信息:

DOI:10.16295/j.cnki.0257-358x.2025.02.003

中图分类号:R259

引用信息:

[1]刘学,李博洋,吴凡,等.“瘀毒”理论指导下从“肺热络瘀”论治特发性肺纤维化[J].山东中医杂志,2025,44(02):141-144+150.DOI:10.16295/j.cnki.0257-358x.2025.02.003.

基金信息:

国家自然科学基金项目(编号:82004285);国家自然科学基金项目(编号:81874442); 泰山学者工程专项经费资助项目(编号:tsqn202306392)

发布时间:

2025-02-05

出版时间:

2025-02-05

检 索 高级检索